<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 57-year-old woman receiving low dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) for <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA) developed a B <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative disease</z:e> (LPD) that was initially considered as large cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of B <z:mp ids='MP_0005384'>cell phenotype</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Epstein-Barr virus (EBV) cytotoxic latent membrane protein-1 (LMP-1) expression was found in some large cells </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative disease</z:e> reversed with MTX discontinuation and without chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>These EBV-associated LPD in patients with RA receiving MTX or other <z:chebi fb="1" ids="35705">immunosuppressive agents</z:chebi> seem to be similar to those triggered by EBV in transplant patients receiving <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> A </plain></SENT>
<SENT sid="4" pm="."><plain>MTX withdrawal and short followup should be considered before chemotherapy since spontaneous regression is possible </plain></SENT>
</text></document>